The Bank of N.T. Butterfield & Son Limited (NTB) EPS Estimated At $0.76; KemPharm, Inc. (KMPH) Had 5 Bullish Analysts

January 18, 2018 - By Adrian Erickson

Analysts expect The Bank of N.T. Butterfield & Son Limited (NYSE:NTB) to report $0.76 EPS on February, 12.They anticipate $0.14 EPS change or 22.58% from last quarter’s $0.62 EPS. NTB’s profit would be $41.55M giving it 13.32 P/E if the $0.76 EPS is correct. After having $0.74 EPS previously, The Bank of N.T. Butterfield & Son Limited’s analysts see 2.70% EPS growth. The stock increased 0.57% or $0.23 during the last trading session, reaching $40.48. About 221,924 shares traded. The Bank of N.T. Butterfield & Son Limited (NYSE:NTB) has 0.00% since January 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 15 analyst reports since August 14, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of KMPH in report on Friday, August 14 with “Outperform” rating. The firm earned “Buy” rating on Monday, September 11 by Canaccord Genuity. Canaccord Genuity maintained KemPharm, Inc. (NASDAQ:KMPH) rating on Thursday, September 17. Canaccord Genuity has “Buy” rating and $34 target. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, August 10 report. Roth Capital initiated the shares of KMPH in report on Wednesday, June 28 with “Buy” rating. The firm has “Buy” rating by Roth Capital given on Friday, August 11. The rating was maintained by RBC Capital Markets with “Buy” on Tuesday, January 16. The rating was reinitiated by Canaccord Genuity on Tuesday, December 20 with “Buy”. As per Friday, May 6, the company rating was maintained by RBC Capital Markets. The stock of KemPharm, Inc. (NASDAQ:KMPH) earned “Outperform” rating by Oppenheimer on Friday, September 18. See KemPharm, Inc. (NASDAQ:KMPH) latest ratings:

16/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $9.0 Maintain
11/09/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0 Maintain
11/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.0000 Maintain
10/08/2017 Broker: Oppenheimer Rating: Buy New Target: $13.0000 Maintain
10/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $7.0000 Maintain

The stock increased 0.96% or $0.049 during the last trading session, reaching $5.149. About 3,503 shares traded. KemPharm, Inc. (NASDAQ:KMPH) has declined 32.16% since January 18, 2017 and is downtrending. It has underperformed by 48.86% the S&P500.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $75.47 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: